Immunovant CFO Executes Tax-Related Stock Sale Amid Recent Clinical Trial Results
Tiago Girao, the Chief Financial Officer of Immunovant, Inc. (NASDAQ:IMVT), completed a sale of 25,760 shares of common stock on April 23, 2026. The transaction, which totaled $763,011, was conducted at a weighted average price of $29.62 per share, with individual prices fluctuating between $29.23 and $30.00. Notably, this sale was not a discretion…